LRC-TriCEPS identified a completely new mechanism of monocyte activation that might be clinically relevant in Alzheimers’ and inflammation diseases. Feb 2023
February 11, 2023
Intro
PDFAbstract
The emerging cytokine tissue inhibitor of metalloproteinases-1 (TIMP-1) correlates with the progression of inflammatory diseases, including cancer. However, the effects of TIMP-1 on immune cell activation and underlying molecular mechanisms are largely unknown. The LRC-TriCEPS platform revealed TIMP-1-interaction with Amyloid Precursor Protein (APP) family members. We found that TIMP-1 triggered glucose uptake and proinflammatory cytokine expression in human monocytes. In cancer patients, TIMP-1 expression positively correlated with proinflammatory cytokine expression and processes associated with monocyte activation. This novel monocyte activation pathway might be clinically relevant for inflammation diseases such as pancreatic cancer but might also be involved in Alzheimers’. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837626/Author
- Celina Eckfeld
- Benjamin Schoeps
- Daniel Haußler
- Julian Fradrich
- Felix Bayer
- Jan Philipp Bottcher
- Percy Knolle
- Simone Heisz
- Olga Prokopchuk
- Hans Hauner
- Enkhtsetseg Munkhbaatar
- Ihsan Ekin Demir
- Chris D. Hermann
- Achim Krüger
Footer
Social Media
